Introduction {#section5-1179554918825450}
============

Liver surgery with complete resection of colorectal cancer liver metastases (CRLMs) improves long-term survival.^[@bibr1-1179554918825450],[@bibr2-1179554918825450]^ In primarily resectable metastases, pre-operative chemotherapy allows selecting patients with better prognosis, maximising remnant liver, and reducing local recurrence compared to surgery alone.^[@bibr3-1179554918825450]^ In unresectable metastases, chemotherapy reduces the disease enabling complete resectioning in 12.5% to 30% of cases.^[@bibr4-1179554918825450]^ Pre-operative chemotherapy based on oxaliplatin and/or irinotecan may be involved in histological damage, vascular lesions, or steatohepatitis, despite conflicting results from studies.^[@bibr5-1179554918825450],[@bibr6-1179554918825450]^ This hepatotoxicity could reduce liver function of the future remnant liver (FRL) and increase post-operative complications.^[@bibr6-1179554918825450],[@bibr7-1179554918825450]^

Nevertheless, risk factors for steatosis and non-alcoholic steatohepatitis (NASH) exist even without any chemotherapy, for example, in obesity and diabetes. Moreover, histological assessment of sinusoidal obstruction syndrome (SOS) and steatohepatitis has limitations and requires an experienced pathologist.^[@bibr8-1179554918825450],[@bibr9-1179554918825450]^ In general, reports in literature on the impact of chemotherapy on non-tumoural liver and on post-operative morbidity and mortality are heterogeneous with contradictory conclusions.^[@bibr10-1179554918825450][@bibr11-1179554918825450][@bibr12-1179554918825450]--[@bibr13-1179554918825450]^

The aim of this study was to investigate the factors associated with hepatotoxicity on non-tumoural liver due to pre-operative chemotherapy. We analysed only patients who received exclusively one line of chemotherapy, operated by parenchymal-sparing surgery with 2 comparative histopathological analyses (a routine pathological examination and an expert assessment).

Methods {#section6-1179554918825450}
=======

Patients {#section7-1179554918825450}
--------

Patients operated on for CRLM, between January 2003 and May 2015, were retrospectively identified from our prospectively maintained database (Base FOI, Medlog™). Patients treated with only one line of pre-operative chemotherapy were included. Patients with chronic liver disease, treated with adjuvant chemotherapy with FOLFOX (and not 5-fluouracil alone) or 2 different lines of pre-operative chemotherapy, were excluded. Details on patient selection and surgical methods are given in [Supplementary Material](https://journals.sagepub.com/doi/suppl/10.1177/1179554918825450).

Histological analysis {#section8-1179554918825450}
---------------------

Histological analysis of non-tumoural hepatic parenchyma was performed using archived material (prepared from formalin-fixed, paraffin-embedded tissue). Morphological analysis was based on haematoxylin and eosin (H&E), Masson trichrome, and reticulin stains. The pathologists were unaware of the clinical data. Patients were excluded when the slides were too close to the metastases or presented surgical hepatitis. First analysis was made by our pathologist followed by a second analysis by an expert from the university hospital. Results from the second analyses were used as reference. In the second part, we analysed inter-observer interpretation and the impact on main results. Histological features of parenchymal, stromal, and vascular changes were evaluated and graded according to Rubbia-Brandt et al^[@bibr5-1179554918825450],[@bibr9-1179554918825450]^ Classification. The standard scores for the evaluation of steatosis and steatohepatitis or NASH were adopted, as defined by Kleiner et al.^[@bibr14-1179554918825450]^

Statistical methods {#section9-1179554918825450}
-------------------

The statistical analyses were performed using SAS software Version 9.3 (Cary, NC). Categorical variables were described using their size and percentages; quantitative variables using their median and range (min-max). In univariate analysis, predictive factors of post-operative complications and of histological lesions were obtained using the chi-square or Fisher exact tests for comparing categorical variables; the Wilcoxon non-parametric test was used to compare continuous variables. A *P* \<.05 was considered to be statistically significant. In multivariate analysis for post-operative complications, significant factors were introduced in a stepwise logistic regression. Weighted kappa scores were used to measure the degree of inter-observer agreement between the 2 pathologists.

Results {#section10-1179554918825450}
=======

Patient characteristics, pre-operative treatment, and surgery {#section11-1179554918825450}
-------------------------------------------------------------

The chemotherapy regimens used every 2 weeks before surgery were as follows:

1.  LV5FU2: folinic acid 400 mg/m^2^ in 2 hours + 5FU 400 mg/m^2^ in 10 minutes + 5FU 2400 mg/m^2^ in 46 hours

2.    with or without bevacizumab 5 mg/kg

3.  FOLFIRI: irinotecan 180 mg/m^2^ in 90 minutes + LV5FU2

4.    with or without bevacizumab 5 mg/kg

5.    with or without panitumumab 6 mg/kg

6.    with or without cetuximab 500 mg/m^2^ every 2 weeks

7.  FOLFOX 4: oxaliplatin 85 mg/m^2^ in 2 hours + LV5FU2

8.    with or without bevacizumab 5 mg/kg

9.    with or without panitumumab 6 mg/kg

10.   with or without cetuximab 500 mg/m^2^

11. FOLFIRINOX: irinotecan 180 mg/m^2^ + oxaliplatin 85 mg/m^2^ + LV5FU2

12.   with or without bevacizumab 5 mg/kg

13.   with or without panitumumab 6 mg/kg

14.   with or without cetuximab 500 mg/m^2^

A total of 319 patients were operated on for CRLM. In total, 153 patients did not meet chemotherapy inclusion criteria. Three had hepatitis virus infection and 76 patients were excluded on histological criteria. Finally, 147 patients matched the inclusion criteria whose clinico-pathological characteristics are given in [Table 1](#table1-1179554918825450){ref-type="table"}. A major liver resection was performed in 58 (39.5%) patients. Intra-operative radiofrequency ablation and resection were performed in 67 patients (45.6% cases). Portal vein obstruction (PVO) by embolisation (by the radiologist) or by ligature plus alcoholisation (during the surgery) was used in 18 patients in whom post-hepatectomy liver failure was considered to be a threat due to a small FRL. Two-stage hepatectomies were planned in 11 cases, but the disease progressed in 4 patients prior to the second intervention, which was cancelled. An extra-hepatic procedure was performed in 66 (44.9%) patients and was potentially contaminating in 38 (25.9%) patients.

###### 

Clinico-pathological characteristics of patients (N = 147).

![](10.1177_1179554918825450-table1)

  Variable                        No. of patients   \%     Number (min-max)
  ------------------------------- ----------------- ------ ------------------
  **Median age, y**                                        64 (34-88)
  **Sex**                                                  
  ** Female**                     61                41.5   
  ** Male**                       86                58.5   
  **Body mass index, kg/m** ^2^                            
  ** Median**                                              25 (17-47)
  ** \<25**                       72                49     
   **⩾25**                        75                51     
   **⩾30**                        19                12.9   
  **Diabetes mellitus**                                    
  ** Present**                    13                8.8    
  ** Absent**                     134               91.2   
  **Arterial hypertension**                                
  ** Present**                    65                44.2   
  ** Absent**                     82                55.8   
  **Dyslipidaemia**                                        
  ** Present**                    37                25.2   
  ** Absent**                     110               74.8   
  **Primary tumour site**                                  
  ** Colon**                      120               81.6   
  ** Rectum**                     27                18.4   
  **Hepatic metastasis**                                   
  ** Synchronous**                111               75.5   
  ** Metachronous**               36                24.5   
  ** Initially resectable**       79                53.7   
  ** Initially unresectable**     68                46.3   

Vascular lesions: predictive and risk factors {#section12-1179554918825450}
---------------------------------------------

Histological lesions in non-tumoural liver were described in 87 (59.2%) patients ([Table 2](#table2-1179554918825450){ref-type="table"}). Vascular lesions, including dilation, nodular regeneration, and peliosis, were considered significant based on our definition in 57 patients (38.8%). Steatohepatitis or NASH was observed in 15 (10.2%) patients and steatosis \>5% in 82 (55.8%) patients.

###### 

Incidence of liver injuries in non-tumoural parenchyma.

![](10.1177_1179554918825450-table2)

  Liver injury                                  No. of patients   \%
  --------------------------------------------- ----------------- ------
  **Sinusoidal dilation**                                         
  ** No**                                       77                52.8
  ** Yes**                                      69                47.2
  **  Grade 1**                                 44                30.1
  **  Grade 2**                                 17                11.6
  **  Grade 3**                                 8                 5.5
  **Nodular regeneration**                                        
  ** No**                                       85                58.2
  ** Yes**                                      61                41.8
  **  Grade 1**                                 38                26.0
  **  Grade 2**                                 13                8.9
  **  Grade 3**                                 10                6.8
  **Vascular toxicity**                                           
  ** No**                                       90                61.2
  ** Yes**                                      57                38.8
  **  Grade \<5**                               126               86.3
  **  Grade ⩾5**                                20                13.7
  **Chemotherapy-associated steatohepatitis**                     
  ** No**                                       132               89.8
  ** Yes**                                      15                10.2
  **Steatosis**                                                   
  ** \<5%**                                     65                44.2
  ** Of 5 at 33%**                              58                39.5
  ** Of 33 at 66%**                             19                12.9
  ** \>66%**                                    5                 3.4
  **Lobular inflammation**                                        
  ** Absent**                                   103               70.1
  ** ⩽2/foci**                                  40                27.2
  ** 2-4/foci**                                 4                 2.7
  ** ⩾4/foci**                                  0                 0
  **Ballooning**                                                  
  ** 0**                                        112               76.2
  ** 1**                                        31                21.1
  ** 2**                                        4                 2.7

Predictive factors for vascular lesions, including congestion and/or nodular lesions, are described in [Table 3](#table3-1179554918825450){ref-type="table"}. In univariate analysis, male sex, pre-operative platelets \<150 g/L, oxaliplatin, and aspartate aminotransferase to platelet ratio index (APRI) score \>0.36 were correlated with the development of vascular lesions. Patients receiving oxaliplatin developed more vascular lesions than without (50% vs 30.5%; *P* = .016). Five patients had abnormally high level of bilirubin before chemotherapy and 10 patients before surgery had more vascular toxicity. In multivariate analysis, sex (*P* = .01), platelets (*P *= .04), and APRI remained correlated with vascular lesions. An APRI score \>0.36 correlated to a higher incidence of vascular lesions: 57.1% vs 28.3% of patients with an APRI score ⩽0.36 (*P* = .02, 134 patients, odds ratio \[OR\] = 2.9; 95% confidence interval \[CI\] = \[1.2-7.3\]). Oxaliplatin and bilirubin levels were not retained as independent risk factors of vascular lesions.

###### 

Predictive factors of vascular histologic lesions in non-tumoural parenchyma.

![](10.1177_1179554918825450-table3)

  Characteristics                 Vascular toxicity (N = 57)   Total   *P*, univariate analysis   *P*, multivariate analysis   OR \[95% CI\]                 
  ------------------------------- ---------------------------- ------- -------------------------- ---------------------------- --------------- ------- ----- -------------------
  Sex                                                                                                                                                        
   Male                           44                           51.2    42                         48.8                         86                            
   Female                         45                           75.0    15                         25.0                         60              .004    .01   0.3 \[0.1-0.8\]
  Chemotherapy with oxaliplatin                                                                                                                              
   Yes                            32                           50.0    32                         50.0                         64                            
   No                             57                           69.5    25                         30.5                         82              .016    NR    
  Chemotherapy with irinotecan                                                                                                                               
   Yes                            59                           67.0    29                         33.0                         88                            
   No                             30                           51.7    28                         48.3                         58              .06           
  Number of cycles                                                                                                                                           
   ⩽8                             46                           61.3    29                         38.7                         75                            
   \>8                            43                           60.6    28                         39.4                         71              .82           
  Targeted therapy                                                                                                                                           
   Bevacizumab                    44                           69.8    19                         30.2                         63                            
   None or other                  45                           54.2    38                         45.8                         83              .55           
  APRI score                                                                                                                                                 
   ⩽0.36                          65                           71.4    26                         28.6                         91                            
   \>0.36                         18                           42.8    24                         57.1                         42              .002    .02   2.9 \[1.2-7.3\]
  Bilirubin before chemotherapy                                                                                                                              
   ⩽1N                            71                           69.6    31                         30.4                         102                           
   \>1N                           1                            20      4                          80                           5               .038    NR    
  Pre-operative bilirubin                                                                                                                                    
   ⩽1N                            65                           69.1    29                         30.9                         94                            
   \>1N                           4                            40      6                          60                           10              .022    NR    
  Pre-operative platelets                                                                                                                                    
   ⩾150 g/L                       86                           66.2    44                         33.8                         130                           
   \<150 g/L                      2                            15.4    11                         84.6                         13              .0003   .04   10.1 \[1.2-89.5\]

Abbreviations: APRI, aspartate aminotransferase to platelet ratio index; CI, confidence interval; NR, not retained at multivariate analysis; OR, odds ratio.

Out of the 2 different types of vascular lesions, congestion lesions and non-nodular lesions tended to associate with pre-operative oxaliplatin (*P* = .064). For patients receiving oxaliplatin, bevacizumab had a protective effect on the development of vascular lesions (*P* = .04). Oxaliplatin seems to have a high impact on the development of severe vascular lesions with severe toxicity in 26.6% of patients against only 3.7% that did not (*P *\< .0001). Number of chemotherapies and the time between the end of chemotherapy and liver surgery had no effect on the incidence of vascular lesions.

Steatohepatitis: predictive and risk factors {#section13-1179554918825450}
--------------------------------------------

In univariate analysis, irinotecan, body mass index (BMI) \>25 kg/m^2^, dyslipidaemia, pre-operative gamma-glutamyltransferase level \>N, and bilirubin \>N were related to more steatohepatitis lesions ([Table 4](#table4-1179554918825450){ref-type="table"}). Multivariate analysis on 15 patients with NASH, irinotecan, and BMI \>25kg/m^2^ remained statistically associated with NASH. In patients treated with or without irinotecan, NASH was observed in 14.8% and 3.4%, respectively (*P* = .01; OR = 7.3; 95% CI = \[1.5-34.7\]); a BMI \>25 kg/m^2^ was linked to more NASH (*P *= .004; OR = 10.0; 95% CI = \[2.1-47.5\]). Neither the duration of chemotherapy nor the delay between surgery and the end of the chemotherapy had an impact on incidence of NASH.

###### 

Predictive factors of NASH in non-tumoural parenchyma.

![](10.1177_1179554918825450-table4)

  Characteristics                 NASH (N = 15)   Total   *P*, univariate analysis   *P*, multivariate analysis   OR \[95% CI\]                 
  ------------------------------- --------------- ------- -------------------------- ---------------------------- --------------- ------ ------ -------------------
  Dyslipidaemia                                                                                                                                 
   Yes                            29              78.4    8                          21.6                         37                            
   No                             101             93.5    7                          6.5                          108             .02    NR     
  Diabetes                                                                                                                                      
   Yes                            10              76.9    3                          23.1                         13                            
   No                             121             91.0    12                         9.0                          133             .13           
  Arterial hypertension                                                                                                                         
   Yes                            56              86.2    9                          13.8                         65                            
   No                             75              92.6    6                          7.4                          81              .20           
  Body mass index                                                                                                                               
   ⩽25 kg/m²                      70              97.2    2                          2.8                          72                            
   \>25 kg/m²                     62              82.7    13                         17.3                         75              .004   .004   10.0 \[2.1-47.5\]
  Chemotherapy with irinotecan                                                                                                                  
   Yes                            75              85.2    13                         14.8                         88                            
   No                             57              96.6    2                          3.4                          59              .03    .01    7.3 \[1.5-34.7\]
  Chemotherapy with oxaliplatin                                                                                                                 
   Yes                            63              96.9    2                          3.1                          65                            
   No                             69              84.1    13                         15.9                         82              .01           
  Number of cycles                                                                                                                              
   ⩽8                             67              88.2    9                          11.8                         76                            
   \>8                            65              91.5    6                          8.5                          71              .50           
  Pre-operative GGT                                                                                                                             
   ⩽1N                            67              93.1    5                          6.9                          72                            
   \>1N                           49              86      8                          14                           57              .045   NR     
  Pre-operative bilirubin                                                                                                                       
   ⩽1N                            89              93.7    6                          6.3                          95                            
   \>1N                           8               80      2                          20                           10              .033   NR     

Abbreviations: CI, confidence interval; GGT, gamma-glutamyltransferase; NASH, non-alcoholic steatohepatitis; NR, not retained at multivariate analysis; OR, odds ratio.

Post-operative outcomes and risk factors {#section14-1179554918825450}
----------------------------------------

In total, 78 patients (53.1%) developed post-operative complications, including 29 (19.7%) major complications and 31 (21.1%) liver-related complications. [Supplementary Table S1](https://journals.sagepub.com/doi/suppl/10.1177/1179554918825450) details the post-operative complications. Ninety-day mortality rate was 0.7% (one septic shock on a post-operative bilioma). Two patients had a splenomegaly, possibly related to chemotherapy.

Risk factors of poorer post-operative outcomes were analysed and are described in [Table 5](#table5-1179554918825450){ref-type="table"}. Patients' characteristics, pre-operative type of treatment, or presence of histological lesions were not correlated to more complications or more liver-related complications.

###### 

Impact of clinico-pathological characteristics, pre-operative treatments, surgery protocols, and histological injuries on post-operative outcomes, in univariate analysis.

![](10.1177_1179554918825450-table5)

  Characteristics           Post-operative complications   Total   *P*, univariate analysis   *P*, multivariate analysis   OR \[95% CI\]                   
  ------------------------- ------------------------------ ------- -------------------------- ---------------------------- --------------- ------ -------- ------------------
  Total                     118                            80.3    29                         19.7                         147                             
  Chemotherapy                                                                                                                                             
   Oxaliplatin              47                             79.7    12                         20.3                         59                              
   Irinotecan               66                             80.5    16                         19.5                         82                              
   Both                     5                              83.3    1                          16.7                         6               .90             
  Number of cycles                                                                                                                                         
   ⩽8                       69                             84.1    13                         15.9                         82                              
   \>8                      66                             78.6    18                         21.4                         84              .36             
  Targeted therapy                                                                                                                                         
   None                     45                             81.8    10                         18.2                         55                              
   Bevacizumab              49                             77.8    14                         22.2                         63                              
   Other                    24                             82.8    5                          17.2                         29              .72             
  Liver surgery extension                                                                                                                                  
   Minor                    71                             79.8    18                         20.2                         89                              
   Major                    47                             81.0    11                         19.0                         58              .85             
  Pre-operative PVO                                                                                                                                        
   Yes                      10                             55.6    8                          44.4                         129                             
   No                       108                            83.7    21                         16.3                         18              .01    .004     5.4 \[1.7-16.6\]
  Two-stage hepatectomy                                                                                                                                    
   Yes                      6                              54.5    5                          45.5                         11                              
   No                       112                            82.4    24                         17.6                         136             .04             
  Extra-hepatic surgery                                                                                                                                    
   Yes                      46                             69.7    20                         30.3                         66                              
   No                       72                             88.9    9                          11.1                         81              .004   NR       
  Septic surgery                                                                                                                                           
   Yes                      23                             60.5    15                         39.5                         38                              
   No                       95                             87.2    14                         12.4                         109             .001   \<.001   5.2 \[2.1-13.1\]
  Vascular lesion                                                                                                                                          
   Absence                  74                             83.2    15                         16.8                         89                              
   Presence                 43                             75.4    14                         24.6                         57              .25             
   Absent or grade \<5      101                            80.2    25                         19.8                         126                             
   Grade ⩾5                 16                             80.0    4                          20.0                         20              .99             
  NASH                                                                                                                                                     
   Absence                  105                            79.6    27                         20.4                         132                             
   Presence                 13                             86.7    2                          13.3                         15              .74             
  APRI score                                                                                                                                               
   ⩽0.36                    73                             79.3    19                         20.7                                                         
   \>0.36                   36                             85.7    6                          14.3                                         .38             

Abbreviations: APRI, aspartate aminotransferase to platelet ratio index; CI, confidence interval; NASH, non-alcoholic associated steatohepatitis; NR, not retained in multivariate analysis; OR, odds ratio; PVO: portal vein obstruction.

In univariate analysis, 4 surgical characteristics were related to poorer outcomes: two-stage hepatic surgeries, PVO, extra-hepatic surgery, and a potentially contaminating procedure. In multivariate analysis, only PVO and septic surgery were associated with more grade ⩾3 post-operative complications. Two-stage hepatectomies (including PVOs) and extra-hepatic surgery (*P *= .14) were not used in the multivariate models. Major complications were associated with a higher blood requirement and a longer time at hospital.

APRI score \>0.36 did not correlate with poorer post-operative outcomes. Among the 25 patients with grade ⩾3 complications and a calculated APRI score, only 6 (24%) had a score \>0.36. Time between the end of chemotherapy and surgery was not significantly different for the occurrence of post-operative complications when two-stage surgeries were excluded. Among the biological parameters, post-operative aspartate aminotransferase (AST) levels below 1.5N during the 2 days after surgery were predictive for complications: 57.1% of patients (4 of 7) with AST ⩽1.5N had severe complications vs 18% (25 of 139 patients) with AST \>2N (*P* = .03).

Comparison of the 2 histological analyses {#section15-1179554918825450}
-----------------------------------------

We compared the histologic descriptions by an expert hepatico-pancreatico-biliary pathologist to those of our general pathologist. Reproducibility was assessed using the Kappa score. For NASH, analyses' agreement was 90.5%, with a Kappa score of 0.53 (moderate agreement). Indeed, 9 patients were considered 'with NASH lesions' and 'without NASH' by our pathologist and the expert, respectively, and 5 patients had a NASH according to the expert and no lesion according to our pathologist, suggesting that among the 15 NASH diagnosed, only one was concordant. For steatosis measurement, comparing no steatosis or steatosis \<5% vs \>5% steatosis, the Kappa score was very high, 0.82 (95% CI = \[0.69-0.95\]). On the contrary, for inflammation and balloon lesion assessments, scoring only agreed at levels expected by chance: *r* = 0.05 and *r* = --0.04.

Regarding vascular lesions, only dilated lesions were analysed by both pathologists. The Kappa score showed a moderate agreement (0.54). A total of 166 patients could be analysed using the routine pathologist assessment results, whereas only 147 patients by the expert analysis; the expert eliminated 19 patients (2 missed strains, 17 lack of non-tumoural liver with presence of surgical hepatitis). According to statistical analyses using our general pathologist results, oxaliplatin and irinotecan were not correlated with higher rates of SOS/sinusoidal dilation and NASH, respectively. These results differ with previously described results from the expert, demonstrating an impact of irinotecan on the incidence of steatohepatitis. Body mass index was correlated with NASH in both analyses. The 2 histological analyses were in agreement to conclude that the presence of histopathological lesions did not worsen post-operative outcomes. Septic surgery was associated with more grade ⩾3 post-operative complications whatever the histological analysis, but PVO was significantly associated with more complications only with the expert results.

Discussion {#section16-1179554918825450}
==========

The aim of this study was to investigate the predisposing factors for hepatotoxicity due to pure first-line pre-operative chemotherapy on the non-tumoural liver, analysed by an expert hepatico-pancreatico-biliary pathologist, and the consequences on surgical outcomes in a series of parenchymal-sparing surgeries. Nevertheless, the main limitation of our work is the lack of a histological assessment of cancer-free liver before chemotherapy.

After 10 years and many studies, results are still heterogeneous, including patients with different and incomparable chemotherapies, without essential and exhaustive histological analysis.^[@bibr10-1179554918825450],[@bibr12-1179554918825450][@bibr13-1179554918825450][@bibr14-1179554918825450][@bibr15-1179554918825450][@bibr16-1179554918825450]--[@bibr17-1179554918825450]^ Our study is interesting as the patients received only one line of chemotherapy, giving us pertinent and homogeneous results on the impact of chemotherapy on liver. The study by Rubbia-Brandt et al^[@bibr9-1179554918825450]^ did not show any impact of sex, contrary to our results.

Probable association between oxaliplatin and vascular lesions {#section17-1179554918825450}
-------------------------------------------------------------

Rubbia-Brandt et al^[@bibr5-1179554918825450],[@bibr9-1179554918825450]^ reported high rates (51%) of vascular lesions after pre-operative chemotherapy with oxaliplatin or irinotecan. In our study, oxaliplatin tended to have an impact on the development of vascular lesions. However, other chemotherapies may also have an effect: 30% of patients receiving no oxaliplatin had vascular lesions. We observed lower incidence of vascular lesions and less severe lesions, probably because of the limited number of pre-operative chemotherapies (only 8 cycles).^[@bibr7-1179554918825450]^ In our results, bevacizumab seems to have a protective effect against vascular toxicity when associated with oxaliplatin, in agreement with previous studies.^[@bibr9-1179554918825450],[@bibr18-1179554918825450]^ Biological predictive factors of vascular lesions were statistically significant: low pre-operative platelets and an APRI score \>0.36. These factors could be useful to select patients with a high risk of vascular toxicity, which should lead to a prudent parenchymal saving surgery.^[@bibr14-1179554918825450],[@bibr18-1179554918825450]^

[Supplementary Table S2](https://journals.sagepub.com/doi/suppl/10.1177/1179554918825450) lists some of the publications on pre-operative chemotherapy and its impact on non-tumoural liver, with some conflicting results.^[@bibr12-1179554918825450],[@bibr15-1179554918825450]^ These differences could be a result of difficulty in diagnosing and assessing vascular lesions, confirming the importance of an expert analysis.^[@bibr9-1179554918825450],[@bibr11-1179554918825450]^ These results are consistent with intra- and inter-observer variations published by Pilgrim et al^[@bibr10-1179554918825450]^ where in the Spearman correlation coefficients were weak, 0.52 and 0.53, respectively.

Probable association between irinotecan and NASH {#section18-1179554918825450}
------------------------------------------------

Irinotecan was implicated by Vauthey et al^[@bibr6-1179554918825450]^ in the incidence of chemotherapy-associated steatohepatitis (CASH) (20.2%). There have been reports on the association between other chemotherapies (5-FU alone, FOLFIRI, or FOLFOX) and CASH.^[@bibr10-1179554918825450],[@bibr19-1179554918825450]^ On the contrary, confounding factors such as BMI or diabetes could influence the development of CASH.^[@bibr8-1179554918825450],[@bibr12-1179554918825450],[@bibr20-1179554918825450]^ The absence of histological differences between pre-existent NASH and CASH may impede understanding the role of irinotecan in the development of steatohepatitis. Of note, NASH is observed in around 5.7% to 17% of the general population.^[@bibr21-1179554918825450]^

Our results are relevant to these studies as NASH and CASH are similar histological lesions with the same pathogenic mechanism. Hence, the risk factors such as BMI, dyslipidaemia, diabetes, and chemotherapy influenced the development of steatohepatitis ([Supplementary Table S2](https://journals.sagepub.com/doi/suppl/10.1177/1179554918825450)). Furthermore, one limitation of our study is the absence of a control group without pre-operative chemotherapy, which we deemed not necessary as this was not the aim of our study. Nevertheless, our population represents the general population, matching on the sex and age proportions, different parameters of metabolic syndrome: diabetes, arterial hypertension, dyslipidaemia, and BMI. Therefore, we can conclude that patients receiving oxaliplatin and not irinotecan have a similar incidence of NASH compared to the general population.^[@bibr22-1179554918825450]^ Our results are consistent with Pilgrim et al,^[@bibr10-1179554918825450]^ with the Spearman correlation coefficients good for steatosis, but not favourable for ballooning and inflammation lesions, as a consequence of steatohepatitis. Moreover, lesions have a heterogeneous distribution inside the liver.^[@bibr23-1179554918825450]^

Correlation between type of neoadjuvant chemotherapy, surgical methods, histological lesions, and post-operative outcomes {#section19-1179554918825450}
-------------------------------------------------------------------------------------------------------------------------

Most of the reports on outcomes impacted by chemotherapies have used non-parenchymal-sparing strategies, where in the quantity of normal parenchyma retrieved at each procedure was possibly more than in our series. Nakano et al^[@bibr7-1179554918825450]^ found that SOS was correlated with an increased risk of post-operative complications but only if a major resection was practised. Sinusoidal lesions have been associated with an increased blood requirement and higher post-operative liver failure,^[@bibr20-1179554918825450],[@bibr24-1179554918825450]^ but no poorer outcomes in other studies.^[@bibr6-1179554918825450],[@bibr12-1179554918825450],[@bibr25-1179554918825450][@bibr26-1179554918825450][@bibr27-1179554918825450]--[@bibr28-1179554918825450]^ The extent of liver resection, and hence the FRL, is a determinant factor for complications.^[@bibr11-1179554918825450],[@bibr29-1179554918825450],[@bibr30-1179554918825450]^ The negative impact of chemotherapy on post-operative outcomes has been suggested by Nordlinger et al,^[@bibr3-1179554918825450]^ but lacked non-tumoural liver analysis. Hepatotoxicity could reduce liver function of the FRL which should not measure below 30% to 40% of liver.^[@bibr6-1179554918825450],[@bibr7-1179554918825450]^ The type and number of chemotherapies may influence these complications with 6 or 8 cycles showing an augmentation of risks.^[@bibr31-1179554918825450],[@bibr32-1179554918825450]^

Potential septic surgery is also known to cause higher post-operative complications.^[@bibr13-1179554918825450],[@bibr28-1179554918825450],[@bibr30-1179554918825450]^ As often in extensive surgeries, PVO was correlated with higher post-operative complications. In the literature, PVO seems to improve liver volume and function,^[@bibr33-1179554918825450]^ but is associated with more post-operative complications (blood loss) and may stimulate the growth of the remaining metastases.^[@bibr34-1179554918825450]^ Rubbia-Brandt et al^[@bibr9-1179554918825450]^ found no impact of PVO on histological non-tumoural liver lesions. On the whole, PVO has to be restricted to the patients having a clear risk of post-hepatectomy liver failure and only if one-stage treatment is not possible.^[@bibr35-1179554918825450]^

Our data have not shown an association between liver injury and outcome. Nevertheless, this retrospective study of 147 patients over a 12-year period is underpowered to demonstrate any association between histological lesions (vascular lesions or steatohepatitis) and post-operative outcomes. Indeed, Vauthey et al^[@bibr6-1179554918825450]^ have demonstrated a 10-fold higher post-operative mortality in the presence of steatohepatitis in a cohort of over 400 patients. Other larger studies on the same topic also conflict with our conclusions.^[@bibr6-1179554918825450],[@bibr10-1179554918825450],[@bibr20-1179554918825450],[@bibr21-1179554918825450]^

Conclusions {#section20-1179554918825450}
===========

The results of our study are in agreement with the literature and show a probable association between the development of NASH and irinotecan and suggest that pre-existent comorbidities may influence this outcome. We also conclude that oxaliplatin seems to lead to higher vascular lesions. Except in specific cases, liver toxicities cannot be used as an argument to proscribe or restrain the use of pre-operative chemotherapy as it is particularly useful in parenchymal-sparing surgery. Nevertheless, our data are underpowered to demonstrate an association between liver injury and outcome.
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